Chest wall Ewing sarcoma family of tumors: long-term outcomes.
OBJECTIVE
To review the 40-year University of Florida experience treating Ewing sarcoma family of tumors of the chest wall.


METHODS
Thirty-nine patients were treated from 1966 to 2006. Of the patients, 22 were treated with radiotherapy (RT) alone, and 17 patients were treated with surgery with or without RT. Of 9 patients with metastatic disease, 8 were treated with RT alone. The risk profiles of each group were otherwise similar. The median age was 16.6 years, and the most frequent primary site was the rib (n=17). The median potential follow-up was 19.2 years.


RESULTS
The 5-year actuarial overall survival (OS), cause-specific survival (CSS), and local control (LC) rates were 34%, 34%, and 72%, respectively. For the nonmetastatic subset (n=30), the 5-year OS, CSS, and LC rates were 44%, 44%, and 79%, respectively. LC was not statistically significantly different between patients treated with RT alone (61%) vs. surgery+RT (75%). None of the 4 patients treated with surgery alone experienced local failure. No patient or treatment variable was significantly associated with local failure. Of the patients, 26% experienced Common Toxicity Criteria (CTC) Grade 3+ toxicity, including 2 pulmonary deaths. Modern intensive systemic therapy helped increase the 5-year CSS from 7% to 49% in patients treated after 1984 (p=0.03).


CONCLUSIONS
This is the largest single-institution series describing the treatment of chest wall Ewing tumors. Despite improvements in survival, obtaining local control is challenging and often accompanied by morbidity. Effort should be focused on identifying tumors amenable to combined-modality local therapy and to improving RT techniques.
Indelicato
Daniel J
DJ
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA. dindelicato@floridaproton.org
Keole
Sameer R
SR
Lagmay
Joanne P
JP
Morris
Christopher G
CG
Gibbs
C Parker
CP
Scarborough
Mark T
MT
Islam
Saleem
S
Marcus
Robert B
RB
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011879:Radiotherapy Dosage; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery*; D035441:Thoracic Wall; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide